You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,722,019


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,722,019
Title:P97 fragments with transfer activity
Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.
Inventor(s): Jefferies; Wilfred (South Surrey, CA), Tian; Mei Mei (Coquitlam, CA), Vitalis; Timothy (Vancouver, CA)
Assignee: biOasis Technologies, Inc. (Vancouver, British Columbia, unknown)
Application Number:13/566,260
Patent Claims:1. An isolated p97 polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-8 and 9.

2. A composition comprising a fragment of p97 that consists of (a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-8 and 9, (b)an amino acid sequence with at least 97% identity along its lenght to a sequence of (a), or (c) an amino acid sequence that differs from a sequence of (a) by the addition or deletion of about 1,2,3,4, or 5 N-terminal and/or C-terminal residues; and a therapeutic or diagnostic agent.

3. The isolated polypeptide of claim 1 labeled with a label selected from the group consisting of fluorescent molecules, luminescent molecules, enzymes, substances having therapeutic activity, toxins, and radionuclides.

4. The isolated polypeptide of claim 1 conjugated to a therapeutic agent or drug.

5. A pharmaceutical composition comprising a therapeutically effective amount of a compound comprising a p97 fragment covalently or operatively linked to a therapeutic agent and a pharmaceutically acceptable excipient, wherein the p97 fragment consists of the amino acid sequence set forth in SEQ ID NO:1-8 or 9.

6. A conjugate, comprising a p97 polypeptide that consists of (a) an amino acid sequence selected from the group consisting of SEQ ID No:1-8 and 9,(b) an amino acid sequence with at least 97% identity along its length to a sequence of (a), or (c) an amino acid sequence that differs from a sequence of (a) by the addition or deletion of about 1,2,3,4, or 5 N-terminal and/or C-terminal residues, where the p97 polypeptide is covalenty or operatively linked to an agent, to form a p97-agent conjugate.

7. The conjugate of claim 6, where the agent is a small molecule, a polypeptide, or a label (detectable entity).

8. The conjugate of claim 7, where the small molecule is a cytotoxic or chemotherapeutic or anti-angiogenic agent selected from one or more of alkylating agents, anti-metabolites, anthracyclines, anti-tumor antiobiotics, platinums, type I topoisomerase inhibitors, type II topoisomerase inhibitors, vinca alkaloids, and taxanes.

9. The conjugate of claim 7, where the small molecule is selected from one or more of chlorambucil, cyclophosphamide, cilengitide, lomustine (CCNU), melphalan, procarbazine, thiotepa, carmustine (BCNU), enzastaurin, busulfan, daunorubicin, doxorubicin, gefitinib, erlotinib idarubicin, temozolomide, epirubicin, mitoxantrone, bleomycin, cisplatin, carboplatin, oxaliplatin, camptothecins, irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide, temsirolimus, everolimus, vincristine, vinblastine, vinorelbine, vindesine, CT52923, paclitaxel, imatinib, dasatinib, sorafenib, pazopanib, sunitnib, vatalanib, geftinib, erlotinib, AEE-788, dichoroacetate, tamoxifen, fasudil, SB-681323, semaxanib, donepizil, galantamine, memantine, rivastigmine, tacrine, rasigiline, naltrexone, lubiprostone, safinamide, istradefylline, pimavanserin, pitolisant, isradipine, pridopidine (ACR16), tetrabenazine, bexarotene, glatirimer acetate, fingolimod, and mitoxantrone, including pharmaceutically acceptable salts and acids thereof.

10. The conjugate of claim 7, where the polypeptide is an antibody or antigen-binding fragment thereof.

11. The conjugate of claim 10, wherein the antibody or antigen-binding fragment thereof specifically binds to one or more of human Her2/neu, Her1/EGFR, CD20, VEGF, CD52, CD33, CTLA-4, tenascin, alpha-4 (.alpha.4) integrin, IL-12, IL-23, the p40 subunit of IL-12/IL-23, amyloid-.beta.(A.beta.), Huntingtin, CD25, nerve growth factor (NGF), TrkA, TNF-.alpha., TNF-.beta., or .alpha.-synuclein.

12. The conjugate of claim 10, where the antibody is selected from one or more of trastuzumab, cetuximab, daclizumab, tanezumab, 3F8, abagovomab, adalimumab, adecatumumab, afutuzumab, alemtuzumab, alacizumab (pegol), amatuximab, apolizumab, bavituximab, bectumomab, belimumab, bevacizumab, bivatuzumab (mertansine), brentuximab vedotin, cantuzumab (mertansine), cantuzumab (ravtansine), capromab (pendetide), catumaxomab, certolizumab, citatuzumab (bogatox), cixutumumab, clivatuzumab (tetraxetan), conatumumab, dacetuzumab, dalotuzumab, detumomab, drozitumab, ecromeximab, edrecolomab, elotuzumab, enavatuzumab, ensituximab, epratuzumab, ertumaxomab, etaracizumab, farletuzumab, FBTA05, figitumumab, flanvotumab, galiximab, gemtuzumab, ganitumab, gemtuzumab (ozogamicin), girentuximab, glembatumumab (vedotin), golimumab, ibritumomab tiuxetan, icrucumab, igovomab, indatuximab ravtansine, infliximab, intetumumab, inotuzumab ozogamicin, ipilimumab (MDX-101), iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab (mertansine), lucatumumab, lumiliximab, mapatumumab, matuzumab, milatuzumab, mitumomab, mogamulizumab, moxetumomab (pasudotox), nacolomab (tafenatox), naptumomab (estafenatox), narnatumab, necitumumab, nimotuzumab, nivolumab, Neuradiab.RTM. (with or without radioactive iodine), NR-LU-10, ofatumumab, olaratumab, onartuzumab, oportuzumab (monatox), oregovomab, panitumumab, patritumab, pemtumomab, pertuzumab, pritumumab, racotumomab, radretumab, ramucirumab, rilotumumab, rituximab, robatumumab, samalizumab, sibrotuzumab, siltuximab, tabalumab, taplitumomab (paptox), tenatumomab, teprotumumab, TGN1412, ticilimumab, tremelimumab, tigatuzumab, TNX-650, tositumomab, TRBS07, tucotuzumab (celmoleukin), ublituximab, urelumab, veltuzumab, volociximab, votumumab, and zalutumumab, including antigen-binding fragments thereof.

13. The conjugate of claim 7, where the polypeptide is an interferon-.beta.polypeptide, or an active fragment or variant thereof.

14. The conjugate of claim 7, where the polypeptide associates with a lysosomal storage disease.

15. The conjugate of claim 14, where the polypeptide is selected from one or more of aspartylglucosaminidase, acid lipase, cysteine transporter, Lamp-2, .alpha.-galactosidase A, acid ceramidase, .alpha.-L-fucosidase,.beta.-hexosaminidase A, GM2-ganglioside activator (GM2A), .alpha.D-mannosidase, .beta.-D-mannosidase, arylsulfatase A, saposin B, neuraminidase, .alpha.-N acetylglucosaminidase phosphotransferase, phosphotransferase .UPSILON.-subunit, L-iduronidase, iduronate-2-sulfatase, heparan-N-sulfatase, .alpha.-N-acetylglucosaminidase, acetylCoA:N acetyltransferase, N-acetylglucosamine 6-sulfatase, galactose 6-sulfatase,.beta.-galactosidase, N-acetylgalactosamine 4-sulfatase, hyaluronoglucosaminidase, sulfatases, palmitoyl protein thioesterase, tripeptidyl peptidase I, acid sphingomyelinase, cathepsin A, cathepsin K, .alpha.-galactosidase B, NPC1, NPC2, sialin, and sialic acid transporter, including active fragments and variants thereof.

16. The conjugate of claim 7, where the detectable entity is selected from one or more of diatrizoic acid, a radioisotope, a fluorophore/fluorescent dye, and a nanoparticle.

17. The conjugate of claim 7, where the agent is a cardiotoxic agent.

18. The conjugate of claim 17, where the cardiotoxic agent is an anthracycline/anthraquinolone, cyclophosphamide, antimetabolite, antimicrotubule agent, tyrosine kinase inhibitor, bevacizumab, or trastuzumab.

19. The conjugate of claim 17, where the cardiotoxic agent is cyclopentenyl cytosine, 5-fluorouracil, capecitabine, paclitaxel, docataxel, adriamycin, doxorubucin, epirubicin, emetine, isotamide, mitomycin C, erlotinib, gefitinib, imatinib, sorafenib, sunitinib, cisplatin, thalidomide, busulfan, vinblastine, bleomycin, vincristine, arsenic trioxide, methotrexate, rosiglitazone, or mitoxantrone.

20. A composition, comprising a conjugate of claim 6, and a pharmaceutically acceptable carrier.

21. The conjugate of claim 7, where the polypeptide is etanercept, or an active fragment or variant thereof.

Details for Patent 8,722,019

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Aytu Bioscience, Inc. PROSTASCINT capromab pendetide Injection 103608 10/28/1996 ⤷  Try a Trial 2031-08-05
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2031-08-05
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2031-08-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.